Seeing Is Believing
Currently out of the existing stock ratings of Brian Cheng, 37 are a BUY (77.08%), 10 are a HOLD (20.83%), 1 are a SELL (2.08%).
Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 38.1% that have a potential upside of 17.58% achieved within 53 days.
Brian Cheng’s has documented 95 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on XNCR, Xencor at 07-Nov-2024.
Analyst best performing recommendations are on APLS (APELLIS PHARMACEUTICALS).
The best stock recommendation documented was for APLS (APELLIS PHARMACEUTICALS) at 10/12/2023. The price target of $46 was fulfilled within 1 day with a profit of $2.1 (4.78%) receiving and performance score of 47.84.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$63
$46.98 (293.26%)
$63
12 days ago
(08-Nov-2024)
14/28 (50%)
$43.37 (220.94%)
165
Buy
$54
3 months 14 days ago
(06-Aug-2024)
3/5 (60%)
$21.39 (65.59%)
559
Buy
$86
$69.98 (436.83%)
$87
6 months 10 days ago
(10-May-2024)
1/3 (33.33%)
$58.74 (215.48%)
75
Buy
$48
$31.98 (199.63%)
$40
9 months 12 days ago
(08-Feb-2024)
4/8 (50%)
$10.09 (26.62%)
195
Buy
$36
1 years 4 months 6 days ago
(14-Jul-2023)
2/2 (100%)
$15.83 (78.48%)
271
Which stock is Brian Cheng is most bullish on?
Which stock is Brian Cheng is most reserved on?
What Year was the first public recommendation made by Brian Cheng?